An impressive panel brought together expertise in product innovation and development, regulatory affairs and the patient voice to consider these challenges and how to address them.
With 14 interactive panel discussions and opportunities for networking, the event provided a forum to share knowledge, ask questions and gain invaluable industry insights.
With no specific antigens available and a highly immunosuppressive microenvironment with little blood flow, how will researchers tackle solid tumors and bring cell therapy to millions?